Search Results - "Denlinger N"

825 - Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MALIGNANCIES.

Authors: Denlinger, N. Bradbury, H. Doseck, N. et al.

Source: Cytotherapy (Elsevier Inc.). 2023 Supplement, Vol. 25 Issue 6, pS178-S179. 2p.

903 - Process Development and Manufacturing: CRYOPRESERVATION METHOD OPTIMIZATION FOR PLACE-OF-CARE MANUFACTURING OF A FIRST IN HUMAN TRI-SPECIFIC CAR T-CELL THERAPY PRODUCT FOR LYMPHOID MALIGNANCIES.

Authors: Denlinger, N. Bradbury, H. Parris, K. et al.

Source: Cytotherapy (Elsevier Inc.). 2022 Supplement, Vol. 24 Issue 5, pS161-S161. 1p.

Retrospective review of cell doses in haploidentical hematopoietic stem cell transplant and associated outcomes.

Authors: Denlinger, N. Zhao, Q. Saad, A. et al.

Source: Cytotherapy (Elsevier Inc.). 2020 Supplement, Vol. 22, pS57-S58. 2p.

Primary chemoradiation for the treatment of locally advanced cervical cancer: Impact of treatment location and time on outcomes.

Authors: Bixel, K. Denlinger, N. Marsh, L. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p152-152. 1p.

Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

Authors: Hofmeister, C.C. Jansak, B. Denlinger, N. et al.

Source: Leukemia Research. Aug2008, Vol. 32 Issue 8, p1295-1298. 4p.

Effect of Radiation Therapy on Outcomes after CAR T-Cell Therapy for Non-Hodgkin Lymphoma.

Authors: Kapoor, N. Mo, X. Sigmund, A. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2022 Supplement, Vol. 114 Issue 3, pe354-e354. 1p.

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies.

Authors: Umyarova E Sharp J Pei C et al.

Source: Blood cancer journal [Blood Cancer J] 2026 Mar 12; Vol. 16 (1). Date of Electronic Publication: 2026 Mar 12.

Publication Type: Letter

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process

89 | TANDEM CD20‐19‐DIRECTED NON‐CRYOPRESERVED CAR‐T CELLS–ZAMTOCABTAGENE AUTOLEUCEL (ZAMTO‐CEL)—IN PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA IN DALY II US STUDY.

Authors: Johnston, P. B. Miklos, D. B. Gupta, N. K. et al.

Source: Hematological oncology 2025 Supplement; Vol. 43.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232

105 | INTERIM RESULTS OF TANDEM CD20‐CD19‐DIRECTED NON‐CRYOPRESERVED CAR‐T CELLS—ZAMTOCABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA.

Authors: Shah, N. N. Maziarz, R. T. Jacobson, C. A. et al.

Source: Hematological oncology 2025 Supplement; Vol. 43.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Authors: Vasu S Denlinger N Song NJ et al.

Source: Research square [Res Sq] 2026 Feb 09. Date of Electronic Publication: 2026 Feb 09.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet ISSN: 2693-5015 (Electronic) Linking ISSN: 26935015 NLM ISO Abbreviation: Res Sq Subsets: PubMed not MEDLINE

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.

Authors: Umyarova E Pei C Pellegrino W et al.

Source: Journal of hematology & oncology [J Hematol Oncol] 2025 Mar 18; Vol. 18 (1), pp. 30. Date of Electronic Publication: 2025 Mar 18.

Publication Type: Letter; Research Support, N.I.H., Extramural

Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.

Authors: Voorhees TJ Bezerra E Denlinger N et al.

Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Oct; Vol. 24 (10), pp. 649-652. Date of Electronic Publication: 2024 Mar 18.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

Isolated oral CD30⁺/CD4⁺ CAR⁺ T cell lymphoma in long-term remission after radiotherapy.

Authors: Bezerra E Lupu L de Lima M et al.

Source: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2025 Dec 03; Vol. 33 (12), pp. 6033-6040. Date of Electronic Publication: 2025 Sep 02.

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

Stem-like CD8⁺ T cells in cancer.

Authors: Steiner C Denlinger N Huang X et al.

Source: Frontiers in immunology [Front Immunol] 2024 Aug 15; Vol. 15, pp. 1426418. Date of Electronic Publication: 2024 Aug 15 (Print Publication: 2024).

Publication Type: Journal Article; Review

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.

Authors: Sharp J Zhao Q Voorhees TJ et al.

Source: British journal of haematology [Br J Haematol] 2025 Sep; Vol. 207 (3), pp. 992-1001. Date of Electronic Publication: 2025 Jun 30.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study.

Authors: Bond, D. A. Wei, L. Yildiz, V. et al.

Source: Hematological oncology Jun2023 Supplement S2; Vol. 41.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232

Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.

Authors: Bajwa A Zhao Q Geer M et al.

Source: Blood advances [Blood Adv] 2025 Jan 14; Vol. 9 (1), pp. 170-175.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.

Authors: Bajwa A Huang Y Li R et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jun; Vol. 63 (6), pp. 1492-1495. Date of Electronic Publication: 2022 Feb 03.

Publication Type: Letter

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.

Authors: Denlinger N Song NJ Zhang X et al.

Source: Blood advances [Blood Adv] 2024 Jun 25; Vol. 8 (12), pp. 3140-3153.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.

Authors: Chan WK Williams J Sorathia K et al.

Source: Experimental hematology & oncology [Exp Hematol Oncol] 2023 Sep 22; Vol. 12 (1), pp. 79. Date of Electronic Publication: 2023 Sep 22.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101590676 Publication Model: Electronic Cited Medium: Print ISSN: 2162-3619 (Print) Linking ISSN: 21623619 NLM ISO Abbreviation: Exp Hematol Oncol Subsets: PubMed not MEDLINE